These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 30772387)

  • 21. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
    Benza RL; Simonneau G; Ghofrani HA; Corris PA; Langleben D; Rosenkranz S; White RJ; Cheng CC; Campos FTAF; Kim HK; Souza R; Chang M; Rahner C; Meier C; Hoeper MM
    J Heart Lung Transplant; 2024 Oct; 43(10):1756-1760. PubMed ID: 38852934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension.
    Lewis RA; Johns CS; Cogliano M; Capener D; Tubman E; Elliot CA; Charalampopoulos A; Sabroe I; Thompson AAR; Billings CG; Hamilton N; Baster K; Laud PJ; Hickey PM; Middleton J; Armstrong IJ; Hurdman JA; Lawrie A; Rothman AMK; Wild JM; Condliffe R; Swift AJ; Kiely DG
    Am J Respir Crit Care Med; 2020 Feb; 201(4):458-468. PubMed ID: 31647310
    [No Abstract]   [Full Text] [Related]  

  • 25. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
    Hoeper MM; Kramer T; Pan Z; Eichstaedt CA; Spiesshoefer J; Benjamin N; Olsson KM; Meyer K; Vizza CD; Vonk-Noordegraaf A; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Huscher D; Pittrow D; Rosenkranz S; Grünig E
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28775047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.
    Frost AE; Badesch DB; Barst RJ; Benza RL; Elliott CG; Farber HW; Krichman A; Liou TG; Raskob GE; Wason P; Feldkircher K; Turner M; McGoon MD
    Chest; 2011 Jan; 139(1):128-37. PubMed ID: 20558556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension.
    Stolfo D; Barbisan D; Ameri P; Lombardi CM; Monti S; Driussi M; Zovatto IC; Gentile P; Howard L; Toma M; Pagnesi M; Collini V; Bauleo C; Guglielmi G; Adamo M; D'Angelo L; Nalli C; Sciarrone P; Moschella M; Zorzi B; Vecchiato V; Milani M; Di Poi E; Airò E; Metra M; Garascia A; Sinagra G; Lo Giudice F
    J Heart Lung Transplant; 2023 Aug; 42(8):1082-1092. PubMed ID: 37005100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of two predictive models for survival in pulmonary arterial hypertension.
    Sitbon O; Benza RL; Badesch DB; Barst RJ; Elliott CG; Gressin V; Lemarié JC; Miller DP; Muros-Le Rouzic E; Simonneau G; Frost AE; Farber HW; Humbert M; McGoon MD
    Eur Respir J; 2015 Jul; 46(1):152-64. PubMed ID: 25837032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
    Sitbon O; Chin KM; Channick RN; Benza RL; Di Scala L; Gaine S; Ghofrani HA; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson VF; Galiè N; Hoeper MM
    J Heart Lung Transplant; 2020 Apr; 39(4):300-309. PubMed ID: 32061506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
    Olsson KM; Delcroix M; Ghofrani HA; Tiede H; Huscher D; Speich R; Grünig E; Staehler G; Rosenkranz S; Halank M; Held M; Lange TJ; Behr J; Klose H; Claussen M; Ewert R; Opitz CF; Vizza CD; Scelsi L; Vonk-Noordegraaf A; Kaemmerer H; Gibbs JS; Coghlan G; Pepke-Zaba J; Schulz U; Gorenflo M; Pittrow D; Hoeper MM
    Circulation; 2014 Jan; 129(1):57-65. PubMed ID: 24081973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting?
    Akaslan D; Aslanger E; Ataş H; Kocakaya D; Yıldızeli B; Mutlu B
    Balkan Med J; 2023 May; 40(3):188-196. PubMed ID: 37000114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
    Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
    Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
    Griffiths M; Simpson CE; Yang J; Vaidya D; Nies MK; Brandal S; Damico R; Hassoun P; Ivy DD; Austin ED; Pauciulo MW; Lutz KA; Martin LJ; Rosenzweig EB; Benza RL; Nichols WC; Manlhiot C; Everett AD
    Chest; 2024 Dec; 166(6):1511-1531. PubMed ID: 39154795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
    Torbicki A; Bacchi M; Delcroix M; Farber HW; Ghofrani HA; Hennessy B; Jansa P; Mehta S; Perchenet L; Pulido T; Rosenberg D; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Wei LJ; Channick R; Benza R
    Circ Cardiovasc Qual Outcomes; 2019 May; 12(5):e005095. PubMed ID: 31109190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.